Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Procuritas Capital Investors VI on its acquisition of Polarn O. Pyret AB
Mandate

Vinge advises Procuritas Capital Investors VI on its acquisition of Polarn O. Pyret AB

March 11, 2021 Employment and Benefits Banking and Finance Commercial Agreements Corporate Crime & Compliance Intellectual Property EU, Competition and Regulatory M&A IT, Telecommunications and Outsourcing

The clothing company Polarn O. Pyret AB is acquired by Procuritas Capital Investors IV from RNB Retail and Brands AB (publ) at a preliminary purchase price of SEK 330 million on a cash and debt-free basis.

Polarn O. Pyret is a Swedish brand for baby and childrenswear that started in 1976 with the goal of making clothes that let kids be kids. Polarn O. Pyret is a leading brand for high-quality kids wear in the Nordics, and their products are sold in several markets around the world.

The transaction is subject to approval by seller’s bondholders and the Swedish Competition Authority.

Vinge’s team consisted of Jonas Johansson together with, among others, Stina Bengtsson and Mikaela Falkner (M&A), Karolina Cohrs (Real estate), Linn Adelwald and Ludvig Wettergren (Banking and Finance), Sara Strandberg and Emil Lindwall (Employment), Christoffer Nordin (Commercial Agreements), Sofia Bergenstråhle (IP), Agnes Perbo (IT), Tove Lövgren Frisk (Compliance), Johan Wahlbom (Competition law) and VDR-specialist Viktoria Owetz Leyva.

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026